Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

[Oxaliplatin in combination with LV5FU2 for advanced/metastatic gastric cancer-a multicenter study]

[Oxaliplatin in combination with LV5FU2 for advanced/metastatic gastric cancer-a multicenter study] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • [Oxaliplatin in combination with LV5FU2 for advanced/metastatic gastric cancer-a multicenter study] Abstract Text:

    mao-lin jinMao-lin Jin,qiang chenQiang Chen,feng-qi chengFeng-qi Cheng,wei chenWei Chen,li chenLi Chen,liang-xi panLiang-xi Pan,yu-fei yangYu-fei Yang,

    OBJECTIVE: To evaluate the effects and safety of OXA-LV5FU2 regimen for patients with advanced/metastatic gastric cancer. METHODS: OXA 100 mg/m(2) i.v. 2hr d1, LV200 mg/m(2) i.v. 2hr followed by 5-Fu 400 mg/m(2) i.v. bolus and 5-Fu 600 mg/m(2) i.v. 22hr d1, 2 were given, and repeated every 2 weeks. Efficacy was evaluated at 4 cycles (8 weeks). RESULTS: Forty three patients have been entered into the study. Patients with primary tumor resected or non-resected were 17 and 26. The evaluable lesions were 26 primary lesions, 22 lymph node metastases, 12 liver metastases, 1 pancreas metastasis and 2 soft tissue metastases. Forty patients were evaluable for clinical response. Four patients achieved CR (10.0%), 13 PR (32.5%), ORR 42.5% (95% CI 27.2 - 57.8), 17 SD (42.5%) and 6 PD (15.0%). Overall response rate (ORR) for chemotherapy naive (1(st) line) and pretreated (2(nd) line) patients were 50.0% (14/28) and 25.0% (3/12), respectively. Median time to progress (mTTP) was 5 months and median overall survival (mOS) was 8 months. Forty-three patients were evaluable for toxicity, with Grade 3, 4 WHO toxicity of neutropenia in 7 patients (16.3%), thrombocytopenia in 3 patients (7.0%), nausea/vomiting in 1 patient (2.3%). There were no Grade 3, 4 peripheral neuropathy toxicity or any deaths during treatment. CONCLUSION: OXA-LV5FU2 is a high response regimen for advanced gastric cancer with mild toxicity, which can be practiced safely.

    [Oxaliplatin in combination with LV5FU2 for advanced/metastatic gastric cancer-a multicenter study] Publishing Authors By Initials

    ml jinML Jin,q chenQ Chen,fq chengFQ Cheng,w chenW Chen,l chenL Chen,lx panLX Pan,yf yangYF Yang,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    [Oxaliplatin in combination with LV5FU2 for advanced/metastatic gastric cancer-a multicenter study] Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Zhonghua zhong liu za zhi [Chinese journal of onco

    VOLUME: 25

    Page Numbers: 172-4

    Journal Abbreviation: Zhonghua Zhong Liu Za Zhi

    ISSN: 0253-3766

    DAY: 10

    MONTH: Mar

    YEAR: 2003

    [Oxaliplatin in combination with LV5FU2 for advanced/metastatic gastric cancer-a multicenter study] Information

    Number of References:

    LANGUAGE: chi

    NlmUniqueID: 7910681

    [Oxaliplatin in combination with LV5FU2 for advanced/metastatic gastric cancer-a multicenter study] Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: [Oxaliplatin in combination with LV5FU2 for advanced/metastatic gastric cancer-a multicenter study] Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for [Oxaliplatin in combination with LV5FU2 for advanced/metastatic gastric cancer-a multicenter study]

    AFFILIATION: Peking University School of Oncology, Beijing Cancer Hospital, Beijing Institute for Cancer Research, Beijing 100036, China.

    Country: China

    China Research PublicationChina Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Zhonghua Zhong Liu Za Zhi

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Oxaliplatin in combination with LV5FU2 for advanced/metastatic gastric cancer-a multicenter study Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News